Overview

* Fulcrum Q3 net loss narrows to $19.6 mln from $21.7 mln last year

* Operating income for Q3 missed analyst expectations

* Fulcrum ended Q3 with $200.6 mln in cash, runway into 2028

Outlook

* Fulcrum expects to release 20 mg dose cohort data by year-end 2025

* Company plans to present additional clinical data at ASH Congress in December 2025

* Fulcrum anticipates cash runway to fund operations into 2028

Result Drivers

* PIONEER TRIAL RESULTS - Encouraging results from 12 mg dose cohort in PIONEER trial showed improvements in fetal hemoglobin and markers of hemolysis

* 20 MG DOSE COHORT - Completed enrollment in 20 mg dose cohort of PIONEER trial, with data expected by year-end

* PIPELINE ADVANCEMENT - Plans to submit IND for bone marrow failure syndromes in Q4 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$19.59

Income mln

Q3 Miss -$21.86 -$20.60

Operatin mln mln (8

g Income Analysts

)

Q3 Basic -$0.31

EPS

Q3 $21.85

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Fulcrum Therapeutics Inc ( FULC ) is $12.50, about 20% above its October 28 closing price of $10.00

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)